SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: 11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-amino-3,3-dimethylbutanoate
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: O=C(C(C(C)(C)C)NC(OC)=O)NN(CC(OC(C(C(C)(C)C)N)=O)C(CC1=CC=CC=C1)NC(C(C(C)(C)C)NC(OC)=O)=O)CC2=CC=C(C3=NC=CC=C3)C=C2
Atazanavir Impurity 19 is chemically 11-benzyl-5,14-di-tert-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-amino-3,3-dimethylbutanoate. Atazanavir Impurity 19 is supplied with detailed characterization data compliant with regulatory guideline. Atazanavir Impurity 19 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Atazanavir.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Determination of Genotoxic impurity in Atazanavir sulphate drug substance by LC-MS
K. Geetha Bhavania , K. Bala Murali Krishnac , N. Srinivasub* , D. Ramachandranc* , N.V.V.S.S. Ramand , B. Hari Babuc*
J Pharm Biomed Anal. 2017 Jan 5;132:156-158
Impact of monomeric vs. micellar surfactant and surfactant-polymer interactions on nucleation-induction times of atazanavir from supersaturated solutions
Anura S. Indulkar, Yi Gao, Shweta Raina, Geoff G.Z. Zhang, and Lynne S. Taylor
Cryst. Growth Des. 2020, 20, 1, 62–72
Simultaneous Determination of Impurities of Atazanavir and Ritonavir in Tablet Dosage Form by Using Reversed-Phase Ultra Performance Liquid Chromatographic Method
Murali Krishna V. V. N. Mantripragada1,*, Sumathi V. Rao1 , Venugopal V. S. Nutulapati2 , and Bhaskara P.V. Mantena1
Journal of Chromatographic Science, 2017, 1–15
Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate
Sreenivasa Rao Chitturi a, Yallappa Somappa Somannavar a, Badarinadh Gupta Peruri a, Sreenivas Nallapati a, Hemant Kumar Sharmaa,∗, Shankar Reddy Budidet a, Vijay Kumar Handaa, Hima Bindu Vurimindi
Journal of Pharmaceutical and Biomedical Analysis 55 (2011) 31–47
A selective and sensitive method development and validation by lc-ms/ms approach for trace level quantification of potential genotoxic impurity of boc epoxide in atazanavir sulphate drug substance
Nelaturi subbaiah1*, gopireddy venkata subba reddy2
Int J Pharm Pharm Sci, Vol 9, Issue 9, 143-148
